{"schema_version":"secwatch.filing_event.v1","accession":"0001140361-24-015456","form_type":"8-K","ticker":"PDSB","cik":"0001472091","company_name":"PDS Biotechnology Corp","filed_at":"2024-03-27T23:59:59+00:00","discovered_at":"2026-05-14T18:03:24.269899+00:00","generated_at":"2026-06-04T07:05:45.815574+00:00","sec_items":["2.02","8.01","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"PDS Biotech prioritizes triple combo for HPV+ HNSCC; 75% 36-mo survival in Ph2","bullets":["Three-year OS of 75% and 75% ORR in ICI-naive advanced HNSCC with PDS01ADC + Versamune HPV + KEYTRUDA.","ICI-resistant group: 72% 12-month OS and 63% ORR at optimal PDS01ADC dose; median OS ~20 months.","Full-year 2023 net loss $42.9M ($1.39/sh) vs $40.9M ($1.43/sh) in 2022; cash $56.6M at Dec 31.","Company raised ~$10.5M net via ATM in Q4 2023 and appointed new CMO and CFO in late 2023/early 2024.","VERSATILE-003 trial deprioritized; potentially pivotal randomized trial of triple combo expected to start in 2024."],"urls":{"canonical":"https://secwatch.observer/filing/0001140361-24-015456","json":"https://secwatch.observer/filing/0001140361-24-015456.json","markdown":"https://secwatch.observer/filing/0001140361-24-015456.md","text":"https://secwatch.observer/filing/0001140361-24-015456.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1472091/000114036124015456/0001140361-24-015456-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1472091/000114036124015456/ef20025224_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-04T07:05:45.815574+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"a79ee9a1f2d17bc4fb4ba516483bbdb883fe927e","claim":"PDS Biotechnology Corp reported the year ended December 31, 2023 results: net income Net loss for the year ended December 31, 2023, was approximately $42.9 million, or $1.39 per basic and diluted share, EPS $1.39 per basic and diluted share.","evidence_excerpt":"Net loss for the year ended December 31, 2023, was approximately $42.9 million, or $1.39 per basic and diluted share, compared to a net loss of $40.9 million, or $1.43 per basic share and diluted share, for the year ended December 31, 2022.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1472091/000114036124015456/0001140361-24-015456-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the year ended December 31, 2023"},{"label":"Net income","value":"Net loss for the year ended December 31, 2023, was approximately $42.9 million, or $1.39 per basic and diluted share"},{"label":"EPS","value":"$1.39 per basic and diluted share"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}